整理 | GLP1减重宝典内容团队 2025年6月3 日 ，信达生物在Clinicaltrials.gov网站上注册了IBI362（玛仕度肽）治疗中至重度肥胖的1/2期临床试验。 | Brief Summary | Study Start (Estimated) . | | --- | --- | | This study is a multicenter, randomized, partially double-blind (double-blind in both | 2025-05-31 | | the IBI362 group and the placebo group, with the tirbopeptide group open), placebo | | | and active drug controlled design study | Primary Completion (Estimated) ● | | | 2026-12-01 | | Official Title | | | Tolerance and Pharmacokinetic/Pharmacokinetic Study ...